Evaxion Biotech reports 69% ORR in Phase 2 trial on EVX-01

Evaxion Biotech A/S (EVAX) announced clinical phase 2 data for its lead compound EVX-01. The data show that 11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate. 15 out of the 16 patients had reduction of their tumors. This topline data is part of a one-year interim analysis of the ongoing phase 2 trial assessing EVX-01 in combination with MSD’s (MRK) anti-PD-1 therapy, KEYTRUDA in patients with advanced melanoma. The complete one-year clinical data will be presented at a poster session at the European Society for Medical Oncology Congress 2024, taking place in Barcelona, Spain, from September 13-17, 2024. “We are very excited about these data, which strongly support both the clinical profile of EVX-01 as a promising personalized cancer treatment and the unique predictive capabilities of our AI-Immunology platform. To present phase 2 efficacy data for an AI-designed vaccine is a major milestone for Evaxion. Huge unmet medical needs remain in the field of melanoma, and we believe that EVX-01 could potentially be an improved treatment option for patientsWe look forward to presenting the complete one-year dataset at ESMO, discussing the data with potential partners and advancing the phase 2 trial towards its completion next year,” says Christian Kanstrup, CEO of Evaxion.